A new report from the Congressional Research Service describes the gene editing technology known as CRISPR-Cas9 and its dramatic implications for genetic engineering. The report also introduces the ethical, regulatory and policy questions that this technology is raising. See Advanced Gene Editing: CRISPR-Cas9, April 28, 2017.
Other new and updated reports from the Congressional Research Service include the following.
Law Enforcement Using and Disclosing Technology Vulnerabilities, April 26, 2017
Renegotiation of the North American Free Trade Agreement (NAFTA): What Actions Do Not Require Congressional Approval?, CRS Legal Sidebar, April 27, 2017
Softwood Lumber Dispute Lumbers On: Preliminary Countervailing Duties on Canadian Softwood Lumber Announced, CRS Legal Sidebar, April 28, 2017
Department of Defense Contractor and Troop Levels in Iraq and Afghanistan: 2007-2017, updated April 28, 2017
American War and Military Operations Casualties: Lists and Statistics, updated April 26, 2017
Armed Conflict in Syria: Overview and U.S. Response, updated April 26, 2017
U.S.-Mexico Economic Relations: Trends, Issues, and Implications, updated April 27, 2017
The Greek Debt Crisis: Overview and Implications for the United States, updated April 24, 2017
Iran’s Nuclear Program: Status, updated April 27, 2017
Confirmation that the construction of the security perimeter and associated security infrastructure at RAF Lakenheath are still ongoing once again raises questions about whether U.S. nuclear weapons have already been deployed to the base.
Alaskans are sensibly pulling back from the vogue for bans and returning to a western tradition that has worked for more than half a century – one that welcomes innovation but also oversees it closely.
The strength of our nation’s data policy isn’t just in the rules we write, but in how effectively we translate those rules into a system that prioritizes the public good. Join us in this movement to design and build more resilient national data policies.
The human cost is measured in deaths. The financial cost is measured in the $52 billion taxpayers pay annually end stage renal disease – double NASA’s budget.